SOURCES SOUGHT
65 -- Promega Brand Name P450-Glo Assay Systems
- Notice Date
- 8/2/2018
- Notice Type
- Sources Sought
- NAICS
- 325413
— In-Vitro Diagnostic Substance Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, 6001 Executive Boulevard, Room 4211, MSC 9559, Bethesda, Maryland, 20892-9559, United States
- ZIP Code
- 20892-9559
- Solicitation Number
- NIHDA201800410
- Archive Date
- 8/22/2018
- Point of Contact
- Mark E. McNally, Phone: (301) 827-5869, Jeffrey Schmidt, Phone: (301) 402-1488
- E-Mail Address
-
mcnallyme@mail.nih.gov, schmidtjr@mail.nih.gov
(mcnallyme@mail.nih.gov, schmidtjr@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- This is a Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding the availability and capability of all qualified sources to perform a potential requirement. This notice is issued to help determine the availability of qualified companies technically capable of meeting the Government requirement and to determine the method of acquisition. It is not to be construed as a commitment by the Government to issue a solicitation or ultimately award a contract. Responses will not be considered as proposals or quotes. No award will be made as a result of this notice. The Government will NOT be responsible for any costs incurred by the respondents to this notice. This notice is strictly for research and information purposes only. Background : Tox21 collaboration between NCATS (then NCGC), NTP, EPA and FDA started with an aim to screen tens of thousands of known drugs and compounds in vitro by reducing the cost and time consuming processes involved in traditional toxiciticy testing methods. Since its inception nearly a decade ago, several screenings against Tox21 compound collection were performed at NCATS by running cell-based assays focused mainly on different targets and toxicity pathways which included nuclear receptor signaling, stress response, developmental toxicology, GPCR/cAMP signaling, and Epigentics etc. All these assays used either luciferase or fluorescence reporter gene technology for readouts. In order to quanitfy the induction/inhibiton of these reporter gene activities, different detection assay systems have been used. Currently we are testing P450-Glo assay systems to eventually screen the Tox21 libraries for testing the effects of drugs and chemical entities on cytochrome P450 enzyme activities. Purpose and Objectives : The Tox21 group (NCATS) requires P450-Glo assay systems (CYP3A4 with Luciferin-PPXE, CYP2D6, and CYP1A2). These assay kits will be used to screen compounds from Tox21 collaboration. Project requirements : the following Promega brand name assay systems are required: Item No. V9910. Quantity: sixty-five (65) units. Description: P450-Glo CYP3A4 screening system with Luciferin-PPXE. Item No. V9890. Quantity: sixty-five (65) units. Description: P450-Glo CYP2D6 screening system. Item No. V9770. Quantity: sixty-five (65) units. Description: P450-Glo CYP1A2 screening system. P450-Glo CYP3A4 with Luciferin-PPXE, CYP2D6, and CYP1A2 assay systems: • These assays are homogeneous, luminescent method for measuring cytochrome P450 CYP3A4, CYP2D6, and CYP1A2 activities. • These assays exhibit exquisite sensitivity, low background signals, and broad dynamic range. • The half-life of the luminescent output is greater than two hours, eliminating the need for luminometers with injectors and allowing batch plate processing. • The formulation also minimizes the incidence of false positives due to inhibition of luciferase by analytes when screening for cytochrome P450 inhibitors. • The luminescent format also eliminates the need for time-consuming analyses. • These assays has the reduced incubation times as the luciferin-based substrates are readily taken up by cells and rapidly converted to luciferin insided the cell. • These assays are very stable for a number of thaw and freeze cycles. Anticipated period of performance : Award is anticipated to be made on August 23, 2018, and delivery of the items is to be within one to three (1-3) days after receipt of order. Other important considerations : Delivery shall be to: National Center for Advancing Translational Sciences 9800 Medical Center Drive Rockville, MD 20850 Capability statement /information sought : Clearly indicate whether respondents must provide, as part of their responses, a capability statement, "white paper," answers to questions/issues, etc. This may include requests for: • respondents' opinions about the difficulty and/or feasibility of the potential requirement or proposed acquisition, possible solutions and approaches that may currently exist in the marketplace, and information regarding innovative ideas or concepts; • information regarding respondents': (a) staff expertise, including their availability, experience, and formal and other training; (b) current in-house capability and capacity to perform the work; (c) prior completed projects of similar nature; (d) corporate experience and management capability; and (e) examples of prior completed Government contracts, references, and other related information; • general information regarding the respondent's estimate or rough order of magnitude of the effort or time that may be required for completion of the work. (NOTE: This type of information may only be requested as part of an RFI. However, care must be exercised in requesting such information. Information requested must be: (a) necessary; (b) broad in scope; and (c) used for planning purposes only. Detailed estimates must not be requested.); The respondent must also provide their DUNS number, organization name, address, point of contact, and size and type of business (e.g., 8(a), HubZone, etc., pursuant to the applicable NAICS code and any other information that may be helpful in developing or finalizing the acquisition requirements. One (1) copy of the response is required and must be in Microsoft Word or Adobe PDF format using 11-point or 12-point font, 8-1/2" x 11" paper size, with 1" top, bottom, left and right margins, and with single or double spacing. The information submitted must be must be in and outline format that addresses each of the elements of the project requirement and in the capability statement /information sought paragraphs stated herein. A cover page and an executive summary may be included but is not required. The response is limited to ten (10) page limit. The 10-page limit does not include the cover page, executive summary, or references, if requested. The response must include the respondents' technical and administrative points of contact, including names, titles, addresses, telephone and fax numbers, and e-mail addresses. All responses to this notice must be submitted electronically to the Contract Specialist and Contracting Officer. Facsimile responses are NOT accepted. The response must be submitted to Contract Specialist Mark McNally at e-mail address mcnallyme@mail.nih.gov, and the response must be received on or before 5:00 PM, Eastern Time, Tuesday, August 7, 2018. " Disclaimer and Important Notes : This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a presolicitation synopsis and solicitation may be published in Federal Business Opportunities. However, responses to this notice will not be considered adequate responses to a solicitation. Confidentiality : No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s)."
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NIDA-01/NIHDA201800410 /listing.html)
- Place of Performance
- Address: 9800 Medical Center Drive, Rockville, Maryland, 20850, United States
- Zip Code: 20850
- Zip Code: 20850
- Record
- SN05018799-W 20180804/180802231656-3d1460940d84d1f9116f44d4a8c3c3c3 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |